RESUMEN

The orphan receptor GPR88 has been implicated in a number of striatal-associated disorders, yet its endogenous ligand has not been discovered. We have previously reported that the amine functionality in the 2-AMPP-derived GPR88 agonists can be replaced with an amide (e.g., 4) without losing activity. Later, we have found that the amide can be replaced with a bioisosteric 1,3,4-oxadiazole with improved potency. Here, we report a further study of amide bioisosteric replacement with a variety of azoles containing three heteroatoms, followed by a focused structure-activity relationship study, leading to the discovery of a series of novel 1,4-disubstituted 1H-1,2,3-triazoles as GPR88 agonists. Collectively, our medicinal chemistry efforts have resulted in a potent, efficacious, and brain-penetrant GPR88 agonist 53 (cAMP EC50 = 14 nM), which is a suitable probe to study GPR88 functions in the brain.

Asunto(s)

Bencenoacetamidas/farmacología , Receptores Acoplados a Proteínas G/agonistas , Triazoles/farmacología , Animales , Bencenoacetamidas/síntesis química , Bencenoacetamidas/farmacocinética , Barrera Hematoencefálica/metabolismo , Cuerpo Estriado/metabolismo , Diseño de Fármacos , Masculino , Ratones Endogámicos C57BL , Ratones Noqueados , Estructura Molecular , Oxadiazoles/síntesis química , Oxadiazoles/farmacocinética , Oxadiazoles/farmacología , Receptores Acoplados a Proteínas G/deficiencia , Relación Estructura-Actividad , Triazoles/síntesis química , Triazoles/farmacocinética

RESUMEN

Receptor-related orphan receptor γ (RORγ) has emerged as an attractive therapeutic target for the treatment of cancer and inflammatory diseases. Herein, we report our effort on the discovery, optimization, and evaluation of benzothiazole and benzimidazole derivatives as novel inverse agonists of RORγ. The representative compound 27h (designated as XY123) potently inhibited the RORγ transcription activity with a half-maximal inhibitory concentration (IC50) value of 64 nM and showed excellent selectivity against other nuclear receptors. 27h also potently suppressed cell proliferation, colony formation, and the expression of androgen receptor (AR)-regulated genes in AR-positive prostate cancer cell lines. In addition, 27h demonstrated good metabolic stability and a pharmacokinetic property with reasonable oral bioavailability (32.41%) and moderate half-life (t1/2 = 4.98 h). Significantly, oral administration of compound 27h achieved complete and long-lasting tumor regression in the 22Rv1 xenograft tumor model in mice. Compound 27h may serve as a new valuable lead compound for further development of drugs for the treatment of prostate cancer.

Asunto(s)

Antineoplásicos/uso terapéutico , Bencenoacetamidas/uso terapéutico , Bencimidazoles/uso terapéutico , Miembro 3 del Grupo F de la Subfamilia 1 de Receptores Nucleares/antagonistas & inhibidores , Neoplasias de la Próstata/tratamiento farmacológico , Animales , Antineoplásicos/síntesis química , Antineoplásicos/farmacocinética , Bencenoacetamidas/síntesis química , Bencenoacetamidas/farmacocinética , Bencimidazoles/síntesis química , Bencimidazoles/farmacocinética , Benzotiazoles/síntesis química , Benzotiazoles/farmacocinética , Benzotiazoles/uso terapéutico , Proliferación Celular/efectos de los fármacos , Agonismo Inverso de Drogas , Estabilidad de Medicamentos , Masculino , Ratones Endogámicos NOD , Ratones SCID , Microsomas Hepáticos/metabolismo , Simulación del Acoplamiento Molecular , Estructura Molecular , Miembro 3 del Grupo F de la Subfamilia 1 de Receptores Nucleares/metabolismo , Ratas Sprague-Dawley , Relación Estructura-Actividad , Ensayos Antitumor por Modelo de Xenoinjerto

RESUMEN

The main protease (Mpro) of the SARS-CoV-2 virus is one focus of drug development efforts for COVID-19. Here, we show that interactive molecular dynamics in virtual reality (iMD-VR) is a useful and effective tool for creating Mpro complexes. We make these tools and models freely available. iMD-VR provides an immersive environment in which users can interact with MD simulations and so build protein complexes in a physically rigorous and flexible way. Recently, we have demonstrated that iMD-VR is an effective method for interactive, flexible docking of small molecule drugs into their protein targets (Deeks et al. PLoS One 2020, 15, e0228461). Here, we apply this approach to both an Mpro inhibitor and an oligopeptide substrate, using experimentally determined crystal structures. For the oligopeptide, we test against a crystallographic structure of the original SARS Mpro. Docking with iMD-VR gives models in agreement with experimentally observed (crystal) structures. The docked structures are also tested in MD simulations and found to be stable. Different protocols for iMD-VR docking are explored, e.g., with and without restraints on protein backbone, and we provide recommendations for its use. We find that it is important for the user to focus on forming binding interactions, such as hydrogen bonds, and not to rely on using simple metrics (such as RMSD), in order to create realistic, stable complexes. We also test the use of apo (uncomplexed) crystal structures for docking and find that they can give good results. This is because of the flexibility and dynamic response allowed by the physically rigorous, atomically detailed simulation approach of iMD-VR. We make our models (and interactive simulations) freely available. The software framework that we use, Narupa, is open source, and uses commodity VR hardware, so these tools are readily accessible to the wider research community working on Mpro (and other COVID-19 targets). These should be widely useful in drug development, in education applications, e.g., on viral enzyme structure and function, and in scientific communication more generally.

Asunto(s)

Antivirales/química , Bencenoacetamidas/química , COVID-19/metabolismo , Proteasas 3C de Coronavirus/metabolismo , Imidazoles/química , SARS-CoV-2/enzimología , Inhibidores de Proteasa Viral/química , Antivirales/farmacocinética , Antivirales/farmacología , Bencenoacetamidas/farmacocinética , Bencenoacetamidas/farmacología , Proteasas 3C de Coronavirus/genética , Cristalización , Ciclohexilaminas , Diseño de Fármacos , Humanos , Enlace de Hidrógeno , Imidazoles/farmacocinética , Imidazoles/farmacología , Simulación del Acoplamiento Molecular , Simulación de Dinámica Molecular , Mutación , Oligopéptidos/química , Oligopéptidos/metabolismo , Conformación Proteica , Piridinas , Relación Estructura-Actividad , Inhibidores de Proteasa Viral/farmacocinética , Inhibidores de Proteasa Viral/farmacología

RESUMEN

A simple and accurate chiral liquid chromatographic method was developed for enantiomeric resolution and determination of 2-(5-fluoro-2-hydroxyphenyl)-2-(1-oxo-2,3-dihydro-1H-isoindol-2-yl)-N-(1,3-thiazol-2-yl)acetamide (EAI045). The enantiomers of EAI045 were baseline resolved on a Chiralpak AD-H (250 mm × 4.6 mm, 5 µm) column using a mobile phase system containing n-hexane: 2-propanol (75: 25 v/v) at a flow rate of 1 mL min-1 at 30°C. The eluted analytes were subsequently detected with an ultraviolet detector at 254 nm. The effects of organic modifiers and temperature on the enantioselectivity and resolution of the enantiomers were evaluated. The calibration curves were plotted within the concentration range between 2 and 600 µg mL-1 (n = 11), and recoveries between 98.74% and 101.52% were obtained, with relative standard deviation < 1.4%. The limit of detection and limit of quantitation for R-enantiomer were 0.94 and 3.07 µg mL-1 and for S-enantiomer were 0.86 and 2.84 µg mL-1, respectively. The validated method was found to be suitable for enantiomeric separation and sufficiently accurate for the determination of enantiomeric purity of EAI045 in bulk drugs.

Asunto(s)

Bencenoacetamidas , Cromatografía Liquida/métodos , Tiazoles , Amilosa/análogos & derivados , Amilosa/química , Animales , Bencenoacetamidas/sangre , Bencenoacetamidas/química , Bencenoacetamidas/aislamiento & purificación , Bencenoacetamidas/farmacocinética , Límite de Detección , Modelos Lineales , Ratones , Fenilcarbamatos/química , Reproducibilidad de los Resultados , Estereoisomerismo , Tiazoles/sangre , Tiazoles/química , Tiazoles/aislamiento & purificación , Tiazoles/farmacocinética

RESUMEN

PURPOSE: To evaluate the vitreous concentration of different nonsteroidal anti-inflammatory drugs (NSAIDs) after topical administration and the related prostaglandin E2 (PGE2) levels in patients undergoing pars plana vitrectomy. METHODS: A prospective, randomized, investigator-masked study was performed. One hundred four patients scheduled for a pars plana vitrectomy for an epiretinal membrane or a macular hole were randomized to receive topical diclofenac 0.1%, indomethacin 0.5%, nepafenac 0.3%, bromfenac 0.09%, or placebo 3 days before surgery. At the beginning of surgery, a sample of undiluted vitreous was collected in each patient to assess NSAIDs concentration and PGE2 levels. RESULTS: The median vitreous concentrations were 203.35 (interquartile range 146.54-264.18) pg/mL for diclofenac, 243.45 (interquartile range 156.96-365.37) pg/mL for nepafenac, 438.21 pg/mL (interquartile range, 282.52-645.87) for its active metabolite amfenac, 350.14 (interquartile range, 290.88-481.95) pg/mL for indomethacin, and 274.59 (245.43-358.25) pg/mL for bromfenac. Vitreous PGE2 levels were significantly lower for all the NSAIDs groups compared with the control group (P < 0.001). A statistically significant higher vitreous PGE2 level was found in the diclofenac group compared with the other NSAIDs groups (P < 0.05). CONCLUSION: Topical NSAIDs achieve sufficient vitreous concentration to decrease vitreous PGE2 levels compared with the control group. The different efficacy in reducing PGE2 concentration may affect the management of posterior segment inflammation.

Asunto(s)

Antiinflamatorios no Esteroideos/administración & dosificación , Dinoprostona/metabolismo , Cuerpo Vítreo/metabolismo , Administración Oftálmica , Anciano , Anciano de 80 o más Años , Antiinflamatorios no Esteroideos/farmacocinética , Bencenoacetamidas/administración & dosificación , Bencenoacetamidas/farmacocinética , Benzofenonas/administración & dosificación , Benzofenonas/farmacocinética , Bromobencenos/administración & dosificación , Bromobencenos/farmacocinética , Cromatografía Líquida de Alta Presión , Diclofenaco/administración & dosificación , Diclofenaco/farmacocinética , Método Doble Ciego , Ensayo de Inmunoadsorción Enzimática , Membrana Epirretinal/metabolismo , Membrana Epirretinal/cirugía , Femenino , Humanos , Indometacina/administración & dosificación , Indometacina/farmacocinética , Masculino , Persona de Mediana Edad , Soluciones Oftálmicas , Fenilacetatos/administración & dosificación , Fenilacetatos/farmacocinética , Estudios Prospectivos , Perforaciones de la Retina/metabolismo , Perforaciones de la Retina/cirugía , Vitrectomía

RESUMEN

Starting from our previously developed c-KIT kinase inhibitor CHMFL-KIT-8140, through a type II kinase inhibitor binding element hybrid design approach, we discovered a novel c-KIT kinase inhibitor compound 18 (CHMFL-KIT-64), which is potent against c-KIT wt and a broad spectrum of drug-resistant mutants with improved bioavailability. 18 exhibits single-digit nM potency against c-KIT kinase and c-KIT T670I mutants in the biochemical assay and displays great potencies against most of the gain-of-function mutations in the juxtamembrane domain, drug-resistant mutations in the ATP binding pocket (except V654A), and activation loops (except D816V). In addition, 18 exhibits a good in vivo pharmacokinetic (PK) profile in different species including mice, rats, and dogs. It also displays good in vivo antitumor efficacy in the c-KIT T670I, D820G, and Y823D mutant-mediated mice models as well as in the c-KIT wt patient primary cells which are known to be imatinib-resistant. The potent activity against a broad spectrum of clinically important c-KIT mutants combining the good in vivo PK/pharmacodynamic properties of 18 indicates that it might be a new potential therapeutic candidate for gastrointestinal stromal tumors.

Asunto(s)

Antineoplásicos/uso terapéutico , Bencenoacetamidas/uso terapéutico , Tumores del Estroma Gastrointestinal/tratamiento farmacológico , Inhibidores de Proteínas Quinasas/uso terapéutico , Proteínas Proto-Oncogénicas c-kit/antagonistas & inhibidores , Quinolinas/uso terapéutico , Animales , Antineoplásicos/síntesis química , Antineoplásicos/metabolismo , Antineoplásicos/farmacocinética , Bencenoacetamidas/síntesis química , Bencenoacetamidas/metabolismo , Bencenoacetamidas/farmacocinética , Proliferación Celular/efectos de los fármacos , Perros , Descubrimiento de Drogas , Femenino , Neoplasias Gastrointestinales/tratamiento farmacológico , Humanos , Masculino , Ratones Endogámicos BALB C , Modelos Moleculares , Estructura Molecular , Mutación , Unión Proteica , Inhibidores de Proteínas Quinasas/síntesis química , Inhibidores de Proteínas Quinasas/metabolismo , Inhibidores de Proteínas Quinasas/farmacocinética , Proteínas Proto-Oncogénicas c-kit/genética , Proteínas Proto-Oncogénicas c-kit/metabolismo , Quinolinas/síntesis química , Quinolinas/metabolismo , Quinolinas/farmacocinética , Ratas Sprague-Dawley , Relación Estructura-Actividad , Ensayos Antitumor por Modelo de Xenoinjerto

RESUMEN

FLZ is a novel anti-Parkinson's disease candidate drug. The main active metabolite is FLZ O-dealkylation (M1) in preclinical studies. A reliable ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) quantitation method was developed for the simultaneous determination of FLZ and M1 with low limits of quantitation in human plasma (0.1 ng/mL) and urine (0.5 ng/mL). The plasma and urine samples were both purified by full-automatic solid phase extraction (SPE) method with ensured high extraction recovery and little matrix effect for both analytes, and then separated on a BEH C18 column (2.1 × 50 mm, 1.7 µm). Detection and quantification were performed using an electrospray ionization (ESI) source in positive mode by multiple reaction monitoring (MRM). The precursor to product ion transitions were monitored at m/z 450.3+→313.2+ for FLZ, m/z 436.3+→299.1+ for M1, m/z 462.6+→142.0+ for [D12]-FLZ (internal standard of FLZ) and m/z 447.2+→125.2+ for [D11]-M1 (internal standard of M1), respectively. This method showed good linearity, accuracy, precision and stability in the range of 0.1-100 ng/mL in plasma and 0.5-500 ng/mL in urine of two analytes. Finally, the developed method was successfully applied to a pharmacokinetic research in Chinese healthy volunteers after oral administration of FLZ tablets.

Asunto(s)

Antiparkinsonianos/análisis , Bencenoacetamidas/análisis , Fenoles/análisis , Extracción en Fase Sólida/métodos , Administración Oral , Antiparkinsonianos/administración & dosificación , Antiparkinsonianos/farmacocinética , Bencenoacetamidas/administración & dosificación , Bencenoacetamidas/farmacocinética , Cromatografía Líquida de Alta Presión/instrumentación , Cromatografía Líquida de Alta Presión/métodos , Voluntarios Sanos , Humanos , Masculino , Fenoles/administración & dosificación , Fenoles/farmacocinética , Extracción en Fase Sólida/instrumentación , Espectrometría de Masa por Ionización de Electrospray , Comprimidos , Espectrometría de Masas en Tándem/instrumentación , Espectrometría de Masas en Tándem/métodos

RESUMEN

EAI045 represents a fourth generation allosteric EGFR TKI compound which targets T790M and C797S EGFR mutants. The study reported herein describes a method to explore the distribution of EAI045 in rat tissues as well as to quantify it in plasma. The method used here is an ultra-performance liquid chromatography-tandem mass spectrometry with high sensitivity and selectivity. An ACQUITY UPLC BEN HILIC column with dimensions of 2.1 × 100 mm, 1.7 µm was used to separate the analytes and IS. As mobile phase acetonitrile as well as 0.1 % of formic acid/water was used combined with an elution gradient and 0.40 mL/min flow rate. This eluent was also used for electrospray ionization in positive ion mode. A mode on multiple reactions monitoring (MRM) was also employed in the quantification. This quantification included the use of targeted segment ions with m/z 384.1→100.8 for EAI045, and m/z 285.1→193.3 for IS, respectively. It was found that the linearity of this method was appropriate and the concentration range could be kept within a range of 2-2000 ng/mL for EAI045 in rat plasma and tissues. The level of EAI045 was found to be highest in the liver, followed by kidneys, lungs and heart. Furthermore, the results provided evidence that EAI045 could be absorbed quickly and distributed widely in different tissue types.

Asunto(s)

Bencenoacetamidas/farmacocinética , Cromatografía Líquida de Alta Presión/métodos , Espectrometría de Masas en Tándem/métodos , Tiazoles/farmacocinética , Animales , Masculino , Ratas , Ratas Sprague-Dawley , Sensibilidad y Especificidad , Distribución Tisular

RESUMEN

Nepafenac is a water-insoluble nonsteroidal antiinflammatory drug that is available as an ophthalmic suspension (Nevanac®). Suspensions are undesirable for 2 reasons: they tend to cause foreign body sensation and lacrimation, which could limit residence time and drug bioavailability. This decreases the amount of time the drug has to reach the site of action, the cornea. Previously, we improved the solubility and ocular permeability of nepafenac by complexing the drug with hydroxypropyl-ß-cyclodextrin. In this study, we used the complex to formulate an ion-activated in situ gel system using sodium alginate, Protanal PH 1033, to increase the residence time and to reduce repeat eye drop instillation. Rheological properties of the formulations revealed that the viscosity of the optimized formulation was increased 30-fold when exposed to the simulated tear fluid (35°C). Permeation studies showed that the drug concentration of the in situ formulations were approximately 10 times higher than the commercial product, Nevanac® (p < 0.001). In addition, the in situ gel formulations had 5-fold higher concentrations of nepafenac retained in the cornea when compared to Nevanac® (p <0.001). Finally, ex vivo drug distribution studies in the porcine eye perfusion model revealed a higher drug retention in various ocular tissues such as cornea, sclera, retina, as compared to Nevanac®.

Asunto(s)

Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/farmacocinética , Bencenoacetamidas/administración & dosificación , Bencenoacetamidas/farmacocinética , Portadores de Fármacos/química , Ojo/metabolismo , Geles/química , Fenilacetatos/administración & dosificación , Fenilacetatos/farmacocinética , 2-Hidroxipropil-beta-Ciclodextrina/química , Administración Oftálmica , Alginatos/química , Animales , Antiinflamatorios no Esteroideos/química , Bencenoacetamidas/química , Disponibilidad Biológica , Córnea/metabolismo , Absorción Ocular , Permeabilidad , Fenilacetatos/química , Solubilidad , Porcinos , Viscosidad

RESUMEN

Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID), currently only available as 0.1% ophthalmic suspension (Nevanac®). This study utilized hydroxypropyl-ß-cyclodextrin (HPBCD) to increase the water solubility and trans-corneal permeation of nepafenac. The nepafenac-HPBCD complexation in the liquid and solid states were confirmed by phase solubility, differential scanning calorimetry (DSC), X-ray diffraction (XRD), Fourier transform infrared spectroscopy (FT-IR), and nuclear magnetic resonance spectroscopy (NMR) analyses. Nepafenac 0.1% ophthalmic solution was formulated using HPBCD (same pH and osmolality as that of Nevanac®) and pig eye trans-corneal permeation was studied versus Nevanac®. Furthermore, nepafenac content in cornea, sclera, iris, lens, aqueous humor, choroid, ciliary body, retina, and vitreous humor was studied in a continuous isolated pig eye perfusion model in comparison to the suspension and Nevanac®. Permeation studies using porcine corneas revealed that the solution formulation had a permeation rate 18 times higher than Nevanac®. Furthermore, the solution had 11 times higher corneal retention than Nevanac®. Drug distribution studies using porcine eyes revealed that the solution formulation enables detectable levels in various ocular tissues while the drug was undetectable by Nevanac®. The ocular solution formulation had a significantly higher drug concentration in the cornea compared to the suspension or Nevanac®.

Asunto(s)

Antiinflamatorios no Esteroideos/química , Bencenoacetamidas/química , Ojo/metabolismo , Fenilacetatos/química , beta-Ciclodextrinas/química , Animales , Bencenoacetamidas/farmacocinética , Soluciones Oftálmicas , Permeabilidad , Fenilacetatos/farmacocinética , Solubilidad , Porcinos

RESUMEN

A10, (3-phenylacetylamino-2,6-piperidinedione), is a natural peptide with broad antineoplastic activity. Recently, in vitro antitumor effect of a new A10 analog [3-(4-methoxybenzoylamino)-2,6-piperidinedione] (MPD) has been verified. However, poor aqueous solubility represents an obstacle towards intravenous formulation of MPD and impedes successful in vivo antitumor activity. To surmount such limitation, MPD microemulsion (MPDME) was developed. A 3122 full factorial design using Design-Expert® software was adopted to study the influence of different parameters and select the optimum formulation (MPDME1). Transmission electron microscopy (TEM) displayed spherical droplets of MPDME1. The cytotoxicity of MPDME1 in Michigan Cancer Foundation 7 (MCF-7) breast cancer cell line exceeded that of MPD solution (MPDS) and tamoxifen. Compatibility with injectable diluents, in vitro hemolytic studies and in vivo histopathological examination confirmed the safety of parenteral application of MPDME1. Molecular docking results showed almost same binding affinity of A10, MPD and 125I-MPD with histone deacetylase 8 (HDAC8) receptor. Accordingly, radioiodination of MPDME1 and MPDS was done via direct electrophilic substitution reaction. Biodistribution of 125I-MPDME1 and 125I-MPDS in normal and tumor (ascites and solid) bearing mice showed high accumulation of 125I-MPDME1 in tumor tissues. Overall, the results proved that MPDME represents promising parenteral delivery system capable of improving antineoplastic activity of MPD.

Asunto(s)

Antineoplásicos/administración & dosificación , Bencenoacetamidas/administración & dosificación , Neoplasias de la Mama/tratamiento farmacológico , Carcinoma de Ehrlich/tratamiento farmacológico , Simulación del Acoplamiento Molecular , Piperidonas/administración & dosificación , Tecnología Farmacéutica/métodos , Animales , Antineoplásicos/química , Antineoplásicos/farmacocinética , Bencenoacetamidas/química , Bencenoacetamidas/farmacocinética , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/patología , Carcinoma de Ehrlich/metabolismo , Carcinoma de Ehrlich/patología , Composición de Medicamentos , Emulsiones , Etanol/química , Femenino , Histona Desacetilasas/metabolismo , Humanos , Inyecciones Intravenosas , Radioisótopos de Yodo , Células MCF-7 , Masculino , Microscopía Electrónica de Transmisión , Piperidonas/química , Piperidonas/farmacocinética , Polisorbatos/química , Conejos , Proteínas Represoras/metabolismo , Distribución Tisular

RESUMEN

This research was aimed to develop and evaluate nepafenac loaded silica nanoparticles dispersed in-situ gel system for the improved treatment of ocular diseases. The blank silica nanoparticles prepared by stober's process showed the particle size of 151 nm to 285 nm with the zeta potential of -19.6 to -31.9 mV. The nepafenac loaded silica nanoparticles were spherical in shape with smooth outer surface. The nepafenac loaded silica nanoparticles dispersed in poloxamer - chitosan in-situ gelling system showed gelling temperature of 32 °C with sustained release of nepafenac and higher permeation (58.79 µg) across the goat cornea than poloxamer - poloxamer (21.18 µg) in-situ gelling system. Hence the developed in-situ gelling system containing nepafenac loaded silica nanoparticle could be a promising tool for the topical delivery of drugs to the eye.

Asunto(s)

Bencenoacetamidas , Portadores de Fármacos , Nanopartículas/química , Fenilacetatos , Dióxido de Silicio , Animales , Bencenoacetamidas/química , Bencenoacetamidas/farmacocinética , Bencenoacetamidas/farmacología , Portadores de Fármacos/química , Portadores de Fármacos/farmacocinética , Portadores de Fármacos/farmacología , Geles , Ratones , Fenilacetatos/química , Fenilacetatos/farmacocinética , Fenilacetatos/farmacología , Células RAW 264.7 , Dióxido de Silicio/química , Dióxido de Silicio/farmacología

RESUMEN

We report here the discovery and pharmacological characterization of N-(1-benzyl-1H-pyrazol-3-yl)-2-phenylacetamide derivatives as potent, selective, brain-penetrating T-type calcium channel blockers. Optimization focused mainly on solubility, brain penetration, and the search for an aminopyrazole metabolite that would be negative in an Ames test. This resulted in the preparation and complete characterization of compound 66b (ACT-709478), which has been selected as a clinical candidate.

Asunto(s)

Bencenoacetamidas/química , Bencenoacetamidas/farmacología , Bloqueadores de los Canales de Calcio/química , Bloqueadores de los Canales de Calcio/farmacología , Canales de Calcio Tipo T/metabolismo , Epilepsia Generalizada/tratamiento farmacológico , Animales , Bencenoacetamidas/metabolismo , Bencenoacetamidas/farmacocinética , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Bloqueadores de los Canales de Calcio/metabolismo , Bloqueadores de los Canales de Calcio/farmacocinética , Perros , Descubrimiento de Drogas , Epilepsia Generalizada/metabolismo , Cobayas , Humanos , Macaca fascicularis , Pirazoles/química , Pirazoles/farmacología , Ratas Wistar , Relación Estructura-Actividad

RESUMEN

A glucokinase activator and a sulfonylurea might be coprescribed to synergize treatment success for type 2 diabetes (T2D). This clinical pharmacology study was designed to investigate the potential glucose-lowering effect or pharmacodynamic (PD), pharmacokinetic (PK), and safety/tolerability interactions between piragliatin and glyburide in T2D patients already taking glyburide but not adequately controlled. This was an open-label, multiple-dose, 3-period, single-sequence crossover design: on days -1, 6, and 12, PD and PK samples were drawn with glyburide alone (period 0), piragliatin + glyburide (period 1), and piragliatin alone (period 2) treatments. The glucose-lowering effect, including fasting plasma glucose (FPG), of piragliatin was more pronounced when it was administered concomitantly with glyburide as compared to piragliatin or glyburide administered alone. However, this enhancement cannot be explained by a potential PK interaction between piragliatin and glyburide. Other than hypoglycemia, there were no clinically relevant safety findings. Thus, the enhanced PD effect warrants further investigation to define the optimal dose combination between glucokinase activators and sulfonylureas with regard to efficacy, safety, and tolerability.

Asunto(s)

Bencenoacetamidas/farmacocinética , Bencenoacetamidas/uso terapéutico , Glucemia/metabolismo , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Activadores de Enzimas/uso terapéutico , Glucoquinasa/metabolismo , Gliburida/uso terapéutico , Hipoglucemiantes/farmacocinética , Hipoglucemiantes/uso terapéutico , Adulto , Anciano , Bencenoacetamidas/efectos adversos , Estudios Cruzados , Diabetes Mellitus Tipo 2/sangre , Método Doble Ciego , Determinación de Punto Final , Activadores de Enzimas/efectos adversos , Activadores de Enzimas/farmacocinética , Femenino , Glucoquinasa/efectos de los fármacos , Gliburida/farmacocinética , Hemoglobina Glucada , Humanos , Hipoglucemiantes/efectos adversos , Insulina/sangre , Masculino , Metformina/uso terapéutico , Persona de Mediana Edad , Fosfato de Sitagliptina/uso terapéutico

RESUMEN

Piragliatin is a CYP3A substrate; its inactive metabolite M4, formed through cytosolic reductase, is reversibly metabolized back to piragliatin through CYP3A. The impact of concomitant CYP3A modifiers thus cannot be predicted. Drinking alcohol under fasting conditions is associated with a recognized glucose-lowering effect, which might be synergistic with piragliatin's hypoglycemic effect. Two exploratory studies were conducted to examine these potential interactions in type 2 diabetes (T2D) patients: 16 completed an open-label, sequential 2-way crossover, 2-arm (randomized to ketoconazole and rifampicin) CYP3A study; another 18 participated in a double-blind, placebo-controlled, randomized 3-way crossover ethanol study. Administration of piragliatin (100-mg single dose) resulted in a 32% Cmax and 44% area under the curve (AUC∞ ) increase in piragliatin exposure without affecting glucose AUC0-6h following ketoconazole (400 mg QD × 5 days); 30% Cmax and 72% AUC∞ decrease in piragliatin exposure with a 13% increase in glucose AUC0-6h following rifampicin (600 mg QD × 5 days); and, unexpectedly, a 32% Cmax and 23% AUC0-6h decrease (no change in AUC∞ ) in piragliatin exposure with a 13% increase in glucose AUC0-6h following alcohol (40-g single dose). In conclusion, a strong CYP3A modifier or concomitant alcohol could lead to a change in exposure to piragliatin with a potential alteration in glucose-lowering effect.

Asunto(s)

Bencenoacetamidas , Inductores del Citocromo P-450 CYP3A/farmacología , Inhibidores del Citocromo P-450 CYP3A/farmacología , Etanol/farmacología , Hipoglucemiantes , Cetoconazol/farmacología , Rifampin/farmacología , Adulto , Anciano , Bencenoacetamidas/sangre , Bencenoacetamidas/farmacocinética , Bencenoacetamidas/farmacología , Bencenoacetamidas/orina , Glucemia/análisis , Estudios Cruzados , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/metabolismo , Diabetes Mellitus Tipo 2/orina , Método Doble Ciego , Femenino , Humanos , Hipoglucemiantes/farmacocinética , Hipoglucemiantes/farmacología , Masculino , Persona de Mediana Edad

RESUMEN

To assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of piragliatin, a double-blind, randomized, placebo-controlled, multiple-ascending-doses study was conducted in patients with type 2 diabetes mellitus (T2D). Fifty-nine T2D patients were given piragliatin or placebo in a dose-escalation design as a single dose on day 1 followed by multiple doses on days 3 through 8 at doses of 10, 25, 50, 100, and 200 mg twice a day (BID) as well as 200 mg every day (QD). Blood and urine samples were collected for PK analysis. PD assessments included plasma glucose, insulin, C-peptide, glucagon, and GLP-1. Piragliatin exposure was dose proportional without appreciable accumulation or food effect. Piragliatin treatment at steady state yielded dose-dependent reductions up to 32.5% and 35.5% for the highest dose in fasting and postprandial plasma glucose. Piragliatin was well tolerated. Mild or moderate hypoglycemia with rapid recovery after sugar-containing drinks or scheduled meals was the only dose-limiting adverse event. It is concluded that multiple doses of piragliatin consistently showed rapid, dose-dependent glucose reduction of fasting and postprandial plasma glucose in T2D patients.

Asunto(s)

Bencenoacetamidas/farmacología , Bencenoacetamidas/farmacocinética , Glucemia/efectos de los fármacos , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Hipoglucemiantes/farmacología , Hipoglucemiantes/farmacocinética , Adulto , Anciano , Bencenoacetamidas/administración & dosificación , Bencenoacetamidas/efectos adversos , Relación Dosis-Respuesta a Droga , Método Doble Ciego , Ayuno , Femenino , Humanos , Hipoglucemiantes/administración & dosificación , Hipoglucemiantes/efectos adversos , Masculino , Persona de Mediana Edad , Periodo Posprandial

RESUMEN

Nepafenac ophthalmic suspensions, 0.1% (NEVANAC(®)) and 0.3% (ILEVRO™), are topical nonsteroidal anti-inflammatory drug (NSAID) products approved in the United States, Europe and various other countries to treat pain and inflammation associated with cataract surgery. NEVANAC is also approved in Europe for the reduction in the risk of postoperative macular edema (ME) associated with cataract surgery in diabetic patients. The efficacy against ME suggests that topical administration leads to distribution of nepafenac or its active metabolite amfenac to the posterior segment of the eye. This article evaluates the ocular distribution of nepafenac and amfenac and the extent of local delivery to the posterior segment of the eye, following topical ocular instillation in animal models. Nepafenac ophthalmic suspension was instilled unilaterally in New Zealand White rabbits as either a single dose (0.1%; one drop) or as multiple doses (0.3%, one drop, once-daily for 4 days, or 0.1% one drop, three-times daily for 3 days and one morning dose on day 4). Nepafenac (0.3%) was also instilled unilaterally in cynomolgus monkeys as multiple doses (one drop, three-times daily for 7 days). Nepafenac and amfenac concentrations in harvested ocular tissues were measured using high-performance liquid chromatography/mass spectrometry. Locally-distributed compound concentrations were determined as the difference in levels between dosed and undosed eyes. In single-dosed rabbit eyes, peak concentrations of locally-distributed nepafenac and amfenac showed a trend of sclera > choroid > retina. Nepafenac peak levels in sub-samples posterior to the eye equator and inclusive of the posterior pole (E-PP) were 55.1, 4.03 and 2.72 nM, respectively, at 0.25 or 0.50 h, with corresponding amfenac peak levels of 41.9, 3.10 and 0.705 nM at 1 or 4 h. By comparison, peak levels in sclera, choroid and retina sub-samples in a band between the ora serrata and the equator (OS-E) were 13- to 40-fold (nepafenac) or 11- to 23-fold (amfenac) higher, indicating an anterior-to-posterior directional concentration gradient. In multiple-dosed rabbit eyes, with 0.3% nepafenac instilled once-daily or 0.1% nepafenac instilled three-times daily, cumulative 24-h locally-distributed levels of nepafenac in E-PP retina were similar between these groups, whereas exposure to amfenac once-daily dosing nepafenac 0.3% was 51% of that achieved with three-times daily dosing of 0.1%. In single-dosed monkey eyes, concentration gradients showed similar directionality as observed in rabbit eyes. Peak concentrations of locally-distributed nepafenac were 1580, 386, 292 and 13.8 nM in E-PP sclera, choroid and retina, vitreous humor, respectively, at 1 or 2 h after drug instillation. Corresponding amfenac concentrations were 21.3, 11.8, 2.58 and 2.82 nM, observed 1 or 2 h post-instillation. The data indicate that topically administered nepafenac and its metabolite amfenac reach pharmacologically relevant concentrations in the posterior eye segment (choroid and retina) via local distribution, following an anterior-to-posterior concentration gradient. The proposed pathway involves a choroidal/suprachoroidal or periocular route, along with an inward movement of drug through the sclera, choroid and retina, with negligible vitreal compartment involvement. Sustained high nepafenac concentrations in posterior segment tissues may be a reservoir for hydrolysis to amfenac.

Asunto(s)

Bencenoacetamidas/farmacocinética , Fenilacetatos/farmacocinética , Segmento Posterior del Ojo/metabolismo , Uveítis Posterior/tratamiento farmacológico , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/farmacocinética , Bencenoacetamidas/administración & dosificación , Cromatografía Líquida de Alta Presión , Modelos Animales de Enfermedad , Instilación de Medicamentos , Macaca fascicularis , Masculino , Soluciones Oftálmicas , Fenilacetatos/administración & dosificación , Segmento Posterior del Ojo/efectos de los fármacos , Conejos , Distribución Tisular , Uveítis Posterior/metabolismo

RESUMEN

PURPOSE: To assess vitreous concentrations of nonsteroidal anti-inflammatory drugs (NSAIDs) and prostaglandin E2 (PGE2) in patients treated with NSAIDs before vitrectomy for macular pucker. METHODS: A prospective, investigator-masked, randomized study was performed in 64 patients scheduled to undergo vitrectomy. The patients were randomized 1:1:1:1 to receive indomethacin 0.5%, bromfenac 0.09%, nepafenac 0.1%, or placebo three times a day. NSAIDs and PGE2 levels were evaluated in vitreous samples collected at the beginning of surgery. RESULTS: Mean (SD) vitreous concentrations of the study drugs were 503.13 (241.1) pg/mL for indomethacin, 302.5 (91.03) pg/mL for bromfenac, and 284.38 (128.2) pg/mL for nepafenac. Mean (SD) vitreous PGE2 levels were 247.9 (140.9) pg/mL for indomethacin, 322.12 (228.1) pg/mL for bromfenac, 448.8 (261.1) pg/mL for nepafenac, and 1,133 (323.9) pg/mL for placebo. All three NSAIDs reduced vitreous PGE2 levels to a statistically significant extent, without a significant difference among them. CONCLUSION: All assessed NSAIDs penetrated the vitreous and lowered basal PGE2 levels. A greater penetration was associated with pseudophakic eyes. The important inhibition of prostaglandins in the retina may have a clinical effect on the management of inflammatory retina diseases.

Asunto(s)

Antiinflamatorios no Esteroideos/administración & dosificación , Dinoprostona/metabolismo , Cuerpo Vítreo/metabolismo , Administración Tópica , Anciano , Anciano de 80 o más Años , Antiinflamatorios no Esteroideos/farmacocinética , Bencenoacetamidas/administración & dosificación , Bencenoacetamidas/farmacocinética , Benzofenonas/administración & dosificación , Benzofenonas/farmacocinética , Disponibilidad Biológica , Bromobencenos/administración & dosificación , Bromobencenos/farmacocinética , Cromatografía Líquida de Alta Presión , Método Doble Ciego , Femenino , Humanos , Indometacina/administración & dosificación , Indometacina/farmacocinética , Masculino , Soluciones Oftálmicas , Fenilacetatos/administración & dosificación , Fenilacetatos/farmacocinética , Estudios Prospectivos , Enfermedades de la Retina/tratamiento farmacológico , Distribución Tisular , Vitrectomía

RESUMEN

To evaluate the potential pharmacokinetic (PK) and pharmacodynamic (PD, glucose-lowering effect) interaction between simvastatin and piragliatin, both CYP3A substrates, 30 patients with type 2 diabetes mellitus participated in this open-label, randomized, 6-sequence, 3-way crossover (William's design) study. During 3 periods, patients were randomized to receive a single dose of 80 mg simvastatin alone, a single dose of 100 mg piragliatin alone, as well as single doses of 80 mg simvastatin and 100 mg piragliatin together. Primary PK and PD parameters were AUCs on dosing days. The ratio of geometric means (90% confidence intervals) of the AUCinf of piragliatin coadministered with simvastatin compared with piragliatin alone was 0.98 (0.92-1.05), whereas that of the AUCinf of simvastatin acid (active metabolite) coadministered with piragliatin compared with simvastatin alone, was 1.02 (0.90-1.16), suggesting lack of pharmacokinetic interaction between piragliatin and simvastatin. Piragliatin's glucose-lowering effect was not affected by coadministration of simvastatin. Overall, administration of piragliatin with simvastatin was without additional clinically relevant adverse effects as well as abnormality in laboratory tests, vital signs, and electrocardiogram parameters. Concomitant administration of simvastatin and piragliatin, both CYP3A substrates, has no clinically relevant effect on the pharmacokinetics of either piragliatin or simvastatin or on the pharmacodynamics for piragliatin.

Asunto(s)

Bencenoacetamidas/sangre , Diabetes Mellitus Tipo 2/sangre , Diabetes Mellitus Tipo 2/tratamiento farmacológico , Activadores de Enzimas/sangre , Glucoquinasa/sangre , Simvastatina/sangre , Adulto , Anciano , Bencenoacetamidas/administración & dosificación , Bencenoacetamidas/farmacocinética , Estudios Cruzados , Interacciones Farmacológicas/fisiología , Quimioterapia Combinada , Activadores de Enzimas/administración & dosificación , Activadores de Enzimas/farmacocinética , Femenino , Humanos , Masculino , Persona de Mediana Edad , Simvastatina/administración & dosificación , Simvastatina/farmacocinética

RESUMEN

Herein we report the radiolabeling and pharmacological investigation of a novel radioligand, the N-cyclobutylmethyl substituted diphenethylamine [(3)H]HS665, designed to bind selectively to the kappa opioid peptide (KOP) receptor, a target of therapeutic interest for the treatment of a variety of human disorders (i.e., pain, affective disorders, drug addiction, and psychotic disorders). HS665 was prepared in tritium-labeled form by a dehalotritiated method resulting in a specific activity of 30.65 Ci/mmol. Radioligand binding studies were performed to establish binding properties of [(3)H]HS665 to the recombinant human KOP receptor in membranes from Chinese hamster ovary cells stably expressing human KOP receptors (CHOhKOP) and to the native neuronal KOP receptor in guinea pig brain membranes. Binding of [(3)H]HS665 was specific and saturable in both tissue preparations. A single population of high affinity binding sites was labeled by [(3)H]HS665 in membranes from CHOhKOP cells and guinea pig brain with similar equilibrium dissociation constants, Kd, 0.45 and 0.64 nM, respectively. Average receptor density of [(3)H]HS665 recognition sites were 5564 and 154 fmol/mg protein in CHOhKOP cells and guinea pig brain, respectively. This study shows that the new radioligand distinguishes and labels KOP receptors specifically in neuronal and cellular systems expressing KOP receptors, making this molecule a valuable tool in probing structural and functional mechanisms governing ligand-KOP receptor interactions in both a recombinant and native in vitro setting.

Asunto(s)

Analgésicos Opioides , Fenetilaminas , Receptores Opioides kappa/metabolismo , Analgésicos/farmacocinética , Analgésicos Opioides/síntesis química , Analgésicos Opioides/química , Analgésicos Opioides/farmacología , Animales , Bencenoacetamidas/farmacocinética , Encéfalo/efectos de los fármacos , Encéfalo/metabolismo , Células CHO , Cricetinae , Cricetulus , Relación Dosis-Respuesta a Droga , Cobayas , Humanos , Naloxona/análogos & derivados , Naloxona/farmacología , Fenetilaminas/síntesis química , Fenetilaminas/química , Fenetilaminas/farmacología , Unión Proteica/efectos de los fármacos , Pirrolidinas/farmacocinética , Ensayo de Unión Radioligante , Receptores Opioides kappa/genética , Factores de Tiempo , Transfección , Tritio/farmacocinética